Heritable GATA2 mutations associated with familial AML-MDS: a case report and review of literatureJuehua Gao, LoAnn Peterson, Marshall S. Horwitz et al.|Journal of Hematology & Oncology|2014Cited by 31
Tissue and plasma-based mechanisms of resistance to first-line osimertinib in EGFR-mutant NSCLC: A multi-institutional cohort.Zofia Piotrowska, Catherine A. Shu, Lanyi Nora Chen et al.|Journal of Clinical Oncology|2023Cited by 9
A Brief Report of a Phase II trial Evaluating Efficacy and Safety of Hypomethylating Agent Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung CancerCynthia X Wei, Shadia I. Jalal, Maitri Kalra et al.|Clinical Lung Cancer|2023Cited by 6
A Phase II study of GT103 in combination with pembrolizumab in refractory, metastatic non–small cell lung cancerHirva Mamdani, Jeffrey Clarke, Alberto Chiappori et al.|Cancer|2025Cited by 3
A phase II trial of monalizumab in combination with durvalumab (MEDI4736) plus platinum-based chemotherapy for first-line treatment of extensive stage small cell lung cancer (MOZART): Hoosier Cancer Research Network LUN21-530 study.Hirva Mamdani, Shadia I. Jalal, Seongho Kim et al.|Journal of Clinical Oncology|2024Cited by 1